B7H3 blockade with retifanlimab and enoblituzumab with anti-PD-1 therapy has been studied in a phase I study demonstrating a favorable ORR and has led to the development of a phase II/III study demonstrating thus far an acceptable safety profile and anti-tumor activity results [124]. The gene discussed is PDCD1; the disease is neoplasm.